AstraZeneca(AZN) - 2025 Q3 - Earnings Call Presentation

Financial Performance (9M 2025) - Total Revenue increased by 11% to $43.236 billion[21, 22] - Product Sales accounted for 95% of Total Revenue, reaching $41.035 billion[21, 22] - Core EPS grew by 15% to $7.04[10, 22] - Net cash inflow from operating activities increased by 37%[23] Financial Performance (Q3 2025) - Total Revenue increased by 10% to $15.191 billion[21, 22] - Product Sales accounted for 95% of Total Revenue, reaching $14.365 billion[21, 22] - Reported EPS increased by 70% to $1.64[21] - Core EPS increased by 12% to $2.38[22] Revenue Breakdown by Therapy Area (9M 2025) - Oncology contributed 43% of Total Revenue, amounting to $18.591 billion, with a growth of 16%[13, 28] - CVRM (Cardiovascular, Renal & Metabolism) accounted for 23% of Total Revenue, amounting to $9.809 billion, with a growth of 13%[13] - Rare Disease contributed 16% of Total Revenue, amounting to $6.8 billion, with a growth of 6%[13, 48] - Respiratory & Immunology (R&I) accounted for 15% of Total Revenue, amounting to $6.493 billion, with a growth of 5%[13] Revenue Breakdown by Geography (9M 2025) - US contributed 43% of Total Revenue, amounting to $18.517 billion, with a growth of 11%[13] - Europe accounted for 21% of Total Revenue, amounting to $9.160 billion, with a growth of 5%[13] - China contributed 12% of Total Revenue, amounting to $5.279 billion, with a growth of 5%[13]